Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Myelodysplastic Syndromes (MDS) Clinical Trials

A listing of Myelodysplastic Syndromes (MDS) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (24) clinical trials

A Phase 3 clinical study for patients using best supportive care (BSC), rigosertib, Any approved or standard-of-care therapy

This is a Phase III, open-label, randomized, controlled, international study. Approximately 360 patients < 82 years of age with MDS classified as RAEB-1, RAEB-2, or RAEB-t who received AZA or DAC for 9 months and/or 9 cycles over 12 months and had their last dose of AZA or DAC within ...


A Phase 1 clinical study for patients with childhood ALL, Acute myeloid leukemia, Preleukemia, Chronic myeloid leukemia, MYELODYSPLASTIC SYNDROME

This will be a Phase 1, open-label study of DS-3032b to assess its safety and tolerability and identify a Maximum Tolerated Dose (MTD)/tentative Recommended Phase II Dose (RP2D) in subjects with refractory or relapsed Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia (CML) in blast phase, or ...


A clinical research study for the treatment of Preleukemia, MYELODYSPLASTIC SYNDROME

The purpose of this study is to see if selinexor will improve the blood counts and bone marrow function in people with your type of MDS.


A clinical trial seeking patients for a research study for the treatment of Preleukemia, MYELODYSPLASTIC SYNDROME

Phase I: To investigate maximum tolerated dose (MTD), safety and tolerability, pharmacokinetics, exploratory biomarker and efficacy of BI 836858 monotherapy in patients with low or intermediate-1 risk myelodysplastic syndromes (MDS) with symptomatic anemia. Phase II: To investigate safety and efficacy of BI 836858 plus Best Supportive Care compared to Best ...


Patients are needed to participate in a clinical research study of Durvalumab, CC-486 (ORAL AZACITIDINE)

Evaluate the safety and efficacy of CC-486 and Durvalumab in Subjects with Myelodysplastic Syndromes who failed to achieve an objective response post iHMA treatment


A clinical trial seeking patients for a research study for the treatment of Blood disorder, Multiple Myeloma, MYELODYSPLASTIC SYNDROME, MYELOPROLIFERATIVE DISORDER, Lymphoma, Preleukemia

Patients with malignant and non-malignant hematologic diseases including severe aplastic anemia (SAA), paroxysmal nocturnal hemoglobinuria (PNH), myelodysplastic syndrome (MDS), acute and chronic leukemias, Hodgkin's and non-Hodgkin's lymphoma and multiple myeloma (MM) can now be cured by allogeneic bone marrow transplantation (BMT). This curative effect has been ascribed to the use ...


A clinical trial sponsored by Sidney Kimmel Comprehensive Cancer Center for a research study for the treatment of ESSENTIAL THROMBOCYTHEMIA, Prolymphocytic Leukemia, Chronic Myeloproliferative Disorders, Plasma Cell Neoplasm, Multiple Myeloma, Polycythemia Vera, Monoclonal gammopathy, Chronic myelomonocytic leukemia, Chronic Lymphocytic Leukemia, MYELODYSPLASTIC SYNDROME, Plasma cell leukemia, Chronic myeloid leukemia, Myelosclerosis with myeloid metaplasia, Preleukemia

The main goal is to learn whether a drug called tacrolimus, which is an immune-lowering drug (an immunosuppressant) given after transplant to help prevent certain complications, can be given safely for a shorter period of time than it has been in the past. The experiences with immunosuppression duration with other ...


A clinical trial to evaluate treatments for patients with Chronic Myelomonocytic Leukemia in Remission, Graft-Versus-Host Disease, Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission, Multiple Myeloma, Acute Myeloid Leukemia in Remission, Waldenstrom's Macroglobulinemia, Severe Aplastic Anemia, Hodgkin's Disease, MYELODYSPLASTIC SYNDROME, Minimal Residual Disease, MYELOPROLIFERATIVE DISORDER, Lymphoma, Preleukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission

PRIMARY OBJECTIVES: I. To determine the cumulative incidence of extensive chronic graft versus host disease (GVHD) at 1 year after transplantation utilizing the novel conditioning/GVHD prophylactic regimen for patients undergoing allogeneic hematopoietic cell transplantation, in patients who do not progress before day 100. SECONDARY OBJECTIVES: I. To evaluate clinical response, ...